NASA signs agreement for a European-provided Orion service module

Jan. 22, 2013 NASA signed an agreement in mid-December for the European Space Agency (ESA) to provide a service module for the Orion spacecraft's Exploration Mission-1 in 2017.

When the Orion spacecraft blasts off atop NASA's Space Launch System rocket in 2017, attached will be the ESA-provided service module -- the powerhouse that fuels and propels the Orion spacecraft.

"Space has long been a frontier for international cooperation as we explore," said Dan Dumbacher, deputy associate administrator for Exploration System Development at NASA Headquarters in Washington. "This latest chapter builds on NASA's excellent relationship with ESA as a partner in the International Space Station, and helps us move forward in our plans to send humans farther into space than we've ever been before."

The agreement primarily maps out a plan for ESA to fulfill its share of operational costs and additional supporting services for the International Space Station by providing the Orion service module and necessary elements of its design for NASA's Exploration Mission-1 in 2017.

There are three major components to the Orion vehicle: the crew capsule, which will carry four astronauts into space on crewed flights and bring them home for a safe landing; the launch abort system, which would pull the crew module to safety in the unlikely event of a life-threatening problem during launch; and the service module, which will house Orion's power, thermal and propulsion systems. The service module is located directly below the crew capsule and will contain the in-space propulsion capability for orbital transfer, attitude control and high-altitude ascent aborts. It also will generate and store power and provide thermal control, water and air for the astronauts. It will remain connected to the crew module until just before the capsule returns to Earth.

"This is not a simple system" said Mark Geyer, Orion Program manager. "ESA's contribution is going to be critical to the success of Orion's 2017 mission."

Exploration Mission-1 in 2017 will be the first integrated flight test with both the Orion spacecraft and NASA's new Space Launch System. It will follow the upcoming Exploration Flight Test-1 in 2014, in which an uncrewed Orion will launch atop a Delta IV Heavy rocket and fly to an altitude of 3,600 miles above Earth's surface, farther than a human spacecraft has gone in 40 years. For the flight test, a test service module is being built by Lockheed Martin.

Exploration Mission-1 in 2017 will launch an uncrewed Orion spacecraft to demonstrate the performance of the integrated Space Launch System rocket and the spacecraft prior to a crewed flight. It will be followed by Exploration Mission-2, which will launch Orion and a crew of four astronauts into space.

"We have a lot to look forward to in the coming years with human exploration," Dumbacher said. "NASA is thrilled to have ESA as a partner as we set out to explore our solar system."

Share this story on Facebook, Twitter, and Google:

Follow this link:

NASA signs agreement for a European-provided Orion service module

NASA and Autodesk Collaborate on Sustainable Building Performance Monitoring

SAN FRANCISCO--(BUSINESS WIRE)--

Autodesk Inc., (ADSK) and NASA Ames Research Center are collaborating to research and develop new technology that can monitor and optimize the operational life-cycle of high performance buildings. Researchers from Autodesk Research and NASA will implement Autodesk Project Dasher technology at the NASA Ames Sustainability Base, a 50,000 square foot office building and showcase for technologies enhancing efficient resource utilization, including those developed by NASA for its space and aeronautics missions. Autodesk Project Dasher is an experimental Building Information Modeling (BIM) based platform that can provide building owners and operators with insight into full life-cycle real-time building performance.

With its specialized sustainability features, and because it was designed in-part using Autodesk software for BIM, the NASA Ames Sustainability Base was an ideal choice for this research project. On-site power generation from photovoltaics and a solid oxide fuel cell provide more electricity than the facility requires and contribute excess capacity to the NASA Ames local grid. Sustainability Base also uses landscape design solutions, remediated ground water, and water reclaimed using NASA technology designed to reduce its potable water footprint by 90 percent when compared to a traditional building of comparable size.

NASA Ames operates Sustainability Base not only as an attractive workspace and a high-performing facility, but as a dynamic laboratory for advancing technologies for the built environment. An accurately detailed building information model, accessible and useful to facility operators, is a critical component to managing buildings effectively. Through our collaboration with Autodesk and implementation of Project Dasher, we hope to optimize the lifecycle operations of, and achieve unprecedented operational efficiencies with, Sustainability Base while helping to contribute to industry best practices for use of BIM in building performance management, said Dr. Rose Grymes, Technical Lead for Sustainability, NASA Ames Research Center.

Autodesk Project Dasher is designed to provide the interactive building management capabilities that will enable the on-going optimization of facility function that is critical in high performance buildings. Autodesk researchers are currently engaged with NASA Ames architects, planners, researchers, and facilities engineers to develop and test the visualization and analytical tools inside Project Dasher to better address the gap between design and operations. This collaboration is part of a Non-Reimbursable Space Act Agreement between NASA Ames and Autodesk, Inc.

Our collaboration with NASA Ames is offering a unique opportunity for Autodesk to develop, augment, test, and validate the use of BIM as a process for building lifecycle management, said Jeff Kowalski, Autodesk chief technology officer. Through this cooperation, we are actively improving and modifying the Project Dasher technology so in the future, facility owners and operators will be able to take a more integrative approach to maintaining the complex balance between energy-saving measures and occupant comfort.

Autodesk Research developed Project Dasher in response to the growing need for tools that can help to continuously evaluate and verify building performance. The goal of Project Dasher is to go beyond existing building dashboards to represent a comprehensive framework for monitoring building performance. Project Dasher acts as a visualization hub where collected data from various sources is intuitively aggregated and presented in 3D. This can enhance the ability of building owners and operators to infer more complex causal relationships pertaining to building performance and overall operational requirements. Autodesk Project Dasher is not currently available for commercial use.

About Autodesk

Autodesk, Inc. is a leader in 3D design, engineering and entertainment software. Customers across the manufacturing, architecture, building, construction, and media and entertainment industries including the last 17 Academy Award winners for Best Visual Effects use Autodesk software to design, visualize and simulate their ideas. Since its introduction of AutoCAD software in 1982, Autodesk continues to develop the broadest portfolio of state-of-the-art software for global markets. For additional information about Autodesk, visit http://www.autodesk.com.

Autodesk and AutoCAD are a registered trademark or trademarks of Autodesk, Inc., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Academy Award is a registered trademark of the Academy of Motion Picture Arts and Sciences. All other brand names, product names or trademarks belong to their respective holders. Autodesk reserves the right to alter product and services offerings, and specifications and pricing at any time without notice, and is not responsible for typographical or graphical errors that may appear in this document.

Excerpt from:

NASA and Autodesk Collaborate on Sustainable Building Performance Monitoring

Blast from the Past: NASA Fires Historic Engine Parts for New Rocket

NASA is reigniting its mighty moon rocket engine using parts retrieved from museums and displays.

Engineers working this month at the Marshall Space Flight Center in Huntsville, Ala., are completing a series of test firings using recovered components from 40-year-old F-1 engines. The 19-foot-tall (5.8 meter) by 12-foot-wide (3.8 meter) Apollo powerhouses launched the space agency's Saturn V rockets on voyages to Earth orbit and to the moon.

Between 1967 and 1973, a total of 65 F-1 engines were launched, five per flight, on 13 Saturn V boosters.

To develop the Space Launch System (SLS), NASA's next generation heavy-lift rocket, engineers are dissecting, refurbishing and re-firing components from the remaining F-1s to gain a better understanding of how the engine was designed and worked. Even four decades later, the F-1 is still the most powerful single-chamber liquid-fueled rocket engine ever developed. [Graphic: Saturn V Moon Rocket Explained]

For these tests, which included a 20-second hot fire on Jan. 10, the team removed a gas generator from an F-1 engine that was stored at Marshall and another in almost pristine condition from the Smithsonian's National Air and Space Museum in Washington, D.C.

From display stand to test stand

"Being able to hold the parts of this massive engine that once took us to the moon, restoring it, and then seeing it come back to life through hot firings and test data has been an amazing experience," Kate Estes, a NASA liquid propulsion systems engineer, said in an agency release.

The team decided to take apart the gas generator, the part of the engine responsible for supplying power to drive the giant F-1's turbopump, because its component parts were small enough to be tested in Marshall's laboratories. The gas generator is often one of the first pieces designed on a new engine because it is a key part for determining the size of the final engine assembly.

Once they had the artifacts-turned-test-samples in hand, Marshall's team used a novel technique called structured light 3D scanning to produce three-dimensional computer-aided design drawings of the gas generator.

"This activity provided us with information for determining how some parts of the engine might be more affordably manufactured using modern techniques," Estes said. "We decided that using modern instrumentation to measure the generator's performance would provide beneficial [data] for NASA and industry."

See the article here:

Blast from the Past: NASA Fires Historic Engine Parts for New Rocket

Solid State Thin Film Battery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2019

NEW YORK, Jan. 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Solid State Thin Film Battery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2019

http://www.reportlinker.com/p01084201/Solid-State-Thin-Film-Battery-Market-Shares-Strategies-and-Forecasts-Worldwide-Nanotechnology-2013-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Electronic_Component_and_Semiconductor

Batteries are changing. Solid state batteries permit units to be miniaturized, standalone, and portable. Solid-state batteries have advantages in power and density: low-power draw and high-energy density. They have limitations in that there is difficulty getting high currents across solidsolid interfaces.

Power delivery is different in solid state thin film batteries, there is more power per given weight. The very small and very thin size of solid state batteries helps to reduce the physical size of the sensor or device using the battery. Units can stay in the field longer. Solid state batteries can store harvested energy. When combined with energy harvesting solid state batteries can make a device stay in the field almost indefinitely, last longer, power sensors better.

Temperature is a factor with batteries. The solid state batteries work in a very broad range of temperatures, making them able to be used for ruggedized applications. Solid state batteries are ecofriendly. Compared with traditional batteries, solid state thin film batteries are less toxic to the environment.

Development trends are pointing toward integration and miniaturization. Many technologies have progressed down the curve, but traditional batteries have not kept pace. The technology adoption of solid state batteries has implications to the chip grid. One key implication is a drive to integrate intelligent rechargeable energy storage into the chip grid. In order to achieve this requirement, a new product technology has been embraced: Solid state rechargeable energy storage devices are far more useful than non-rechargeable devices.

Thin film battery market driving forces include creating business inflection by delivering technology that supports entirely new capabilities. Sensor networks are creating demand for thin film solid state devices. Vendors doubled revenue and almost tripled production volume from first quarter. Multiple customers are moving into production with innovative products after successful trials.

A solid state battery electrolyte is a solid, not porous liquid. The solid is denser than liquid, contributing to the higher energy density. Charging is complex. In an energy-harvesting application, where the discharge is only a little and then there is a trickle back up, the number of recharge cycles goes way up. The cycles increase by the inverse of the depth of discharge. Long shelf life is a benefit of being a solid state battery. The fact that the battery housing does not need to deal with gases and vapors as a part of the charging/discharging process is another advantage.

According to IBM, the world continues to get "smaller" and "flatter." Being connected holds new potential: the planet is becoming smarter because sensors let us manage the environment. Intelligence is being infused into the way the world works.

See original here:

Solid State Thin Film Battery: Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2019

2013 Louis-Jeantet Prize for Medicine

Public release date: 22-Jan-2013 [ | E-mail | Share ]

Contact: Marianne Morard morard@jeantet.ch 41-227-043-637 European Molecular Biology Organization

The 2013 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the geneticist, Michael Stratton, director of the Wellcome Trust Sanger Institute in Cambridge, and jointly to the German biochemists Peter Hegemann, researcher at the Department of Experimental Biophysics at the Humboldt University, Berlin, and Georg Nagel, researcher at the Institute Julius-von-Sachs at the Biocenter, University of Wurzburg.

The LOUIS-JEANTET FOUNDATION grants the sum of CHF 700'000 for each of the two 2013 prizes, of which CHF 625'000 is for the continuation of the prize-winner's work and CHF 75'000 for their personal use.

THE PRIZE-WINNERS are conducting fundamental biological research which is expected to be of considerable significance for medicine.

MICHAEL STRATTON is awarded the 2013 Louis-Jeantet Prize for Medicine for his work aimed at understanding the genetic causes of human cancer.

The British researcher is one of the worldwide leaders in the study of cancer genomics and genetics. He notably directed the team that discovered the BRCA2 gene which, when mutated, causes predisposition to breast and ovarian cancer. Through the Cancer Genome Project started in 2000 at the Wellcome Trust Sanger Institute under his aegis, Michael Stratton demonstrated the presence of mutations in the BRAF gene in 60% of cases of malignant melanoma. Eight years later this discovery led to the development of new, and for the first time successful, treatments against this serious form of skin cancer.

Michael Stratton will use the prize money to conduct further research into cancer genetics at the early developmental stages.

PETER HEGEMANN and GEORG NAGEL are jointly awarded the 2013 Louis-Jeantet Prize for Medicine for their discovery of ion channels that can be activated by light. They have thus created a new and most promising discipline in the field of neurosciences - "optogenetics".

Peter Hegemann showed that photosensitive proteins controlled the movements of the microscopic green alga Chlamydomonas reinhardtii, which only moves in function of its exposure to light. Georg Nagel showed that rhodopsins from microbes, including the ones from the alga, can be brought into animal cells where they function well and their working can be studied. Together they studied the functionality of these proteins in depth. They thus discovered the unique property of ion channels that may be activated under exposure to light and are usable for the study of neural circuits in vitro and in vivo with so far unmatched levels of precision. The two researchers thus initiated a new discipline optogenetics - that offers an entirely new perspective for the treatment of certain neurological diseases in particular.

Follow this link:

2013 Louis-Jeantet Prize for Medicine

Research and Markets: Radiology, Radiation Therapy and Nuclear Medicine, 3rd Edition 2013

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/zdxf5h/radiology) has announced the addition of the "Radiology, Radiation Therapy and Nuclear Medicine, 3rd Edition 2013" report to their offering.

Clinical review criteria guidelines for radiology (including indications for MRI/CT), radiation therapy and nuclear medicine.

Health plan and Medicare benefit interpretations with useful references and related web links.

Some Key Topics Covered: Please click here for a full list

Radiology: Bone Mass Measurement/Bone mineral density (BMD) testing; Skeletal surveys in children; Scoliosis in children - indications for radiography; Cardiac scans for CAD; Cerebral angiography; Chest x-rays, routine; Cinedefecography; Contrast media; Spine - diagnostic radiology in adults and children; Imaging studies in acute low back pain; Myelography and Cisternography; Discography; Epidurogram/Epiduroscopy;

Breast imaging studies: Diaphanography of the breast; Mammography, screening or diagnostic/Digital/CAD mammography; Magnetic Resonance Imaging of the Breast: Differential Diagnosis; Breast Ultrasound and Echography; Stereotactic Breast Biopsy;

Diagnostic radiology: General; Extremity x-rays; Knee trauma;

MRI and CT scans: Computerized Tomography (CT) or Computerized Axial Tomography (CAT) - Overview; Computerized Tomography (CT or CAT) including extracranial head, brain and thoracic scans; High-resolution CT (HRCT) for Pulmonary Studies; CT for appendicitis; Spiral CT Scans for Lung Cancer Screening; Helical CT for Pulmonary Embolism Detection; Computerized Axial Tomography (CT) Scans: Pelvis, Abdomen, Abdomen and Pelvis - on the same day; Electron-beam CT screening for coronary artery disease; Ultrasound of peripheral sites (tibia, phalanges) for the selection of patients for pharmacologic treatment of osteoporosis;

Neuroimaging Studies for Headaches; Metastatic bone disease: Radiologic evaluation; Percutaneous Drainage/Aspiration of Abscesses and Fluid Collection; Percutaneous Permanent Inferior Vena Cava Placement; Percutaneous Transcatheter Embolization; Percutaneous Transluminal Angioplasty (PTA); Peripheral Vascular Disease Evaluation; Renal Artery Stenosis - Angiography and Stent Placement; Spiral CT for Lung Cancer Screening; Thermography;

See more here:

Research and Markets: Radiology, Radiation Therapy and Nuclear Medicine, 3rd Edition 2013

Cannabis Science May Unlock the Future of Biotech and Medicine

NEW YORK, January 23, 2013 /PRNewswire/ --

At the forefront of revolutionary medicine, Cannabis Science, Inc. (CBIS) [Full Research Report][1] has been heavily investing in the research and development of cannabis, otherwise known as marijuana. With focus on utilizing the medicinal use of marijuana, Cannabis Science is looking to bring medical treatments to areas such as cancer, PTSD and HIV. If the company achieves its goals, detractors may soon become supporters.

Debates on the use of marijuana have been growing despite its legalization in 18 states for medicinal purposes and 2 states for recreational use. While medical professionals continue to investigate and to further assess the benefits and risks of the drug, Cannabis Science is focused toward developing solutions within this new and ever expanding marketplace. Further driving the point home, Colorado recently granted recreational use of marijuana to its residents, a perfect fit for Cannabis Science's current base of operations.

Remaining Conservative

Being in Colorado is an advantage for Cannabis Science to let its business take-off. However, choosing to maintain a controlled position in terms of developing a still controversial drug is probably the company's smartest move. Although most Colorado residents would disagree, the executives of Cannabis Science may have already thought of the repercussions that may curb their business in the near future.

Finding cure for illnesses that are somewhat unheeded is the key to Cannabis Science's future success. If the company decides to follow its current trajectory, their stance towards medicinal revolution may attract more investors. It may seem to be a gamble for some investors, but for those who have bolder minds and wish to invest in high reward ventures, Cannabis Science is an investment that may be the key to unlock the future of biotechnology and medicine.

Reference Links:

[1] The Full Research Report on Cannabis Science, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/6b90_CBIS]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks.

Read more from the original source:

Cannabis Science May Unlock the Future of Biotech and Medicine

Top Three Regenerative Medicine Companies Targeting Ischemic Conditions

As we discussed in our first article on elite regenerative medicine companies, there are several methodologies to delineating the cream of the crop. In this exercise, we will take a look at the impact that regenerative medicine technologies can have on ischemic conditions where tissue in the heart, brain, organs or limbs are damaged as a result of restricted blood flow and identify some of the most innovative companies that have a strong upside based on the products and technologies they are developing, stage of development, and current valuations.

Ischemic conditions are expansive, covering common conditions such as stroke, heart disease and peripheral vascular disease (which in severe cases can result in critical limb ischemia, requiring amputation of digits or limbs). The economic impact of these types of conditions is also substantial. Research by the American Heart Association indicates that cardiovascular disease (most of which is ischemic in nature) comprises more than $300 billion in healthcare related expenses annually, accounting for more than 17% of total healthcare related expenses in the U.S. Furthermore, these conditions impose a huge quality of life burden for patients and their families, and therefore are areas of great unmet medical need.

From a company and investor perspective, they represent multi-billion-dollar opportunities. Cumulatively, hundreds of millions of people are affected globally, but traditional medicines and clinical treatments provide little benefit. Regenerative medicine technologies represent new options that could yield a new age of therapies and viable solutions for patients that presently have very few, if any, options.

In our initial article, Cytomedix, Inc. (OTCQX:CMXI) was omitted from the top five because of the broad scope of credentials defining companies with obvious headroom for growth. Within the parameters of ischemia-related treatments, however, the Gaithersburg, Maryland-based developer of biologically active regenerative therapies deserves a strong mention.

Cytomedix is developing platelet technologies for orthopedics and wound care and a pipeline of autologous (patient-derived) stem cell therapies for tissue repair. The company is already generating revenue through its AutoloGel System, a platelet rich plasma (PRP) producing device for exuding wounds, and its Angel Whole Blood Separation System, a blood processing device for separating whole blood into red cells, platelet poor plasma (PPP) and PRP for use in surgical and orthopedic settings. For the third quarter of 2012, total revenues increased 15% to $1.76 million from $1.53 million in the year prior quarter.

Honing in on the ischemic conditions, through the acquisition of Aldagen in February at a bargain price of $16 million in stock (plus additional shares upon milestones being met), Cytomedix gained control of Aldagens proprietary ALDH bright cell (ALDHbr) technology and finally made the transition from just a wound care company to cement its position as a leading developer of a promising new therapy to treat patients that have recently suffered a stroke.

The ALDHbr technology is used to isolate biologically active stem cells which have previously shown the potential to promote cell and tissue regeneration in preclinical studies. The cells are isolated from the patients own bone marrow, shipped to the company for subsequent expansion, and are then reinfused into the patient roughly 3 weeks later. A 100-patient Phase 2 trial for the treatment of ischemic stroke using ALDHbr Bright Cells derived from a patients own bone marrow is underway that will involve patients from 12 to 15 sites in the United States. Safety data from the first 10 patients in the Phase II RECOVER-Stroke study of ALD-401 were recently presented at the World Stroke Congress in Brazil showing a solid safety profile.

The clinical trials aim to build upon promising laboratory research. Mice treated with ALD-401 two weeks after an induced stroke demonstrated nearly four-fold improvement in motor function compared to controls. Further, stark improvements were seen in ALD-401 slowing decreases in brain volume and the reversal of decline in stroke-induced cell viability. Additional studies with ALD-401 in animal models showed perfusion (blood flow) levels returning to normal after four weeks in stroke-induced subjects receiving the ALDHbr cell treatment while untreated controls remained impaired.

This study is only one of several clinical trials being conducted to test Cytomedixs ALDHbr technology. ALD-201 has completed a Phase I clinical trial testing its safety as a therapeutic candidate for ischemic heart failure. The 20-patient trial showed ALD-201 to be well-tolerated and produced a statistically significant reduction in ischemia as well as improvement in MaxVO2, a measure of the bodys ability to take up oxygen during exercise, in patients receiving the ALDHbr therapy as compared to a placebo group.

In a 21-patient Phase 1/2 clinical trial on ALD-301 testing critical limb ischemia with no revascularization options, the treatment was again well-tolerated with data indicating improved blood flow. Patients with this condition face a 35% risk of limb amputation, but 10 of the 11 patients (91%) treated with ALD-301 required no such procedure.

Here is the original post:

Top Three Regenerative Medicine Companies Targeting Ischemic Conditions

Research and Markets: Personalized Medicine – Scientific and Commercial Aspects – 2013 Report

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vkkh7b/personalized) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.

The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics,pharmacoproteomics, and metabolomics. Basic technologies of molecular diagnostics play an important role, particularly those for single nucleotide polymorphism (SNP) genotyping. Diagnosis is integrated with therapy for selection of the treatment as well for monitoring the results. Biochip/microarray technologies are also important and finally bioinformatics is needed to analyze the immense amount of data generated by various technologies.

Pharmacogenetics, the study of influence of genetic factors on drug action and metabolism, is used for predicting adverse reactions of drugs. Several enzymes are involved in drug metabolism of which the most important ones are those belonging to the family of cytochrome P450. The knowledge of the effects of polymorphisms of genes for the enzymes is applied in drug discovery and development as well as in clinical use of drugs. Cost-effective methods for genotyping are being developed and it would be desirable to include this information in the patient's record for the guidance of the physician to individualize the treatment. Pharmacogenomics, a term that overlaps with pharmacogenetics but is distinct, deals with the application of genomics to drug discovery and development. It involves the mechanism of action of drugs on cells as revealed by gene expression patterns. Pharmacoproteomics is an important contribution to personalized medicine as it is a more functional representation of patient-to-patient variation than that provided by genotyping. A 'pharmacometabonomic' approach to personalizing drug treatment is also described.

Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic strategies using monoclonal bodies can be directed at specific genetic and immunologic targets. Ex vivo gene therapy involves the genetic modification of the patient's cells in vitro, prior to reimplantation of these cells in the patient's body.

Various technologies are integrated to develop personalized therapies for specific therapeutic areas described in the report. Examples of this are genotyping for drug resistance in HIV infection, personalized therapy of cancer, antipsychotics for schizophrenia, antidepressant therapy, antihypertensive therapy and personalized approach to neurological disorders. Although genotyping is not yet a part of clinically accepted routine, it is expected to have this status by the year 2016.

Increase in efficacy and safety of treatment by individualizing it has benefits in financial terms. Information is presented to show that personalized medicine will be cost-effective in healthcare systems. For the pharmaceutical companies, segmentation of the market may not leave room for conventional blockbusters but smaller and exclusive markets for personalized medicines would be profitable. Marketing opportunities for such a system are described with market estimates from 2011-2021.

Profiles of 279 companies involved in developing technologies for personalized medicines, along with 500 collaborations are included in the part II of the report. Finally the bibliography contains over 650 selected publications cited in the report. The report is supplemented by 65 tables and 18 figures.

Key Topics Covered:

Executive Summary

Read the original:

Research and Markets: Personalized Medicine - Scientific and Commercial Aspects - 2013 Report

Foundation Medicine Appoints Steven J. Kafka, Ph.D. as Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced the appointment of Steven J. Kafka, Ph.D. to the newly created position of chief business officer. In this role, he will have broad responsibility for business development and operational functions.

Foundation Medicine is poised to expand the community of physicians, cancer centers and pharmaceutical partners utilizing our services, said Michael J. Pellini, M.D., president and chief executive officer. Steve brings a valuable combination of strategic planning, financial and operational expertise to help us drive capacity enhancements in our world-class CLIA-licensed laboratory, as well as a strong track record of building and leading successful pharmaceutical partnerships. On behalf of the whole team, its our pleasure welcome Steve to Foundation Medicine.

Dr. Kafka brings over 15 years of business and strategy experience in the pharmaceutical and biotechnology industries, with a focus on targeted therapies in oncology. He joins the company from Aileron Therapeutics where he served as chief operating officer and chief financial officer. At Aileron, Dr. Kafka led the company's operations, finance, and human resources functions, and helped to secure a major collaboration with Roche worth up to $1.1 billion.

Prior to Aileron, Dr. Kafka led finance, investor and public relations and business operations as vice president of finance for Infinity Pharmaceuticals (INFI). While at Infinity, he worked on a number of innovative collaborations with leading pharmaceutical companies, including the companys strategic alliance with Purdue Pharmaceuticals. Earlier in his career, Dr. Kafka was senior director of finance at Millennium Pharmaceuticals, where he was a key member of the product team in driving strategic planning and alliance management efforts for VELCADE, a novel targeted cancer therapeutic. Dr. Kafka earned his Ph.D. from Harvard University and his B.A. with Distinction and Honors from Stanford University.

Foundation Medicine is leading a transformation in cancer care where each patients cancer can be treated at the level of its molecular blueprint, said Dr. Kafka. By helping to expand the availability of advanced genomic analysis and rational targeted therapies, we are working to ensure that physicians in communities across the world can select the right treatment at the right time for each patients individual cancer. I am delighted to join Foundation Medicine in this mission.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical assay, FoundationOneTM, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

VELCADE is a registered trademark of Millennium Pharmaceuticals, Inc. Foundation Medicine is a registered trademark, and FoundationOneTMis a trademark of Foundation Medicine, Inc.

See the original post here:

Foundation Medicine Appoints Steven J. Kafka, Ph.D. as Chief Business Officer

ETSU top medical school teacher stepping down

JOHNSON CITY, Tenn. -

East Tennessee State University's top medical school leader is stepping down -- Dr. Philip Bagnell, the Dean of the James H. Quillen College of Medicine, announced Tuesday he will retire this summer.

Bagnell became a faculty member more than two decades ago. He was the school's first full-time pediatric gastroenterologist.

School officials called Bagnell a highly respective leader and true champion for medical education and interdisciplinary learning.

Bagnell said he feels the College of Medicine and the university are in a good place right now. "We are attracting the brightest and best in east Tennessee. And that gives us the best chance for the future," he said.

Bagnell will continue to serve as dean until he officially retires July 31.

Bagnell, who is from Canada, said he and his wife are looking forward to moving back to Nova Scotia and being full-time grandparents.

More here:

ETSU top medical school teacher stepping down

ETSU medical school dean stepping down

JOHNSON CITY, Tenn. -

East Tennessee State University's top medical school leader is stepping down -- Dr. Philip Bagnell, the Dean of the James H. Quillen College of Medicine, announced Tuesday he will retire this summer.

Bagnell became a faculty member more than two decades ago. He was the school's first full-time pediatric gastroenterologist.

School officials called Bagnell a highly respective leader and true champion for medical education and interdisciplinary learning.

Bagnell said he feels the College of Medicine and the university are in a good place right now. "We are attracting the brightest and best in east Tennessee. And that gives us the best chance for the future," he said.

Bagnell will continue to serve as dean until he officially retires July 31.

Bagnell, who is from Canada, said he and his wife are looking forward to moving back to Nova Scotia and being full-time grandparents.

Go here to read the rest:

ETSU medical school dean stepping down